Tag: Bradykinin b2 receptor antagonist

Since the patent for the brand-name drug Firazyr expired in July 2019, multiple FDA-approved generic versions of **Icatibant acetate** have become available. This development has provided patients with hereditary angioedema (HAE) with a more accessible and often more affordable treatment option for acute attacks.

According to the U.S. Food and Drug Administration (FDA), a generic drug is required to be an exact copy of the active ingredient in a brand-name medication, with the same safety and effectiveness. This fundamental principle helps clarify the distinction behind the question: **What is the difference between icatibant and Firazyr?** In short, icatibant is the generic name for the active ingredient, while Firazyr is one of its brand-name versions.

Hereditary Angioedema (HAE) is a rare genetic disorder affecting about 1 in 50,000 people worldwide. For those living with this condition, understanding acute treatments is crucial. So, **what is the drug FIRAZYR used for?** It is an injectable medication for acute attacks of HAE in adults.